Related Experiment Videos
[Haemodynamic effect of dobutamine in cardiac failure (author's transl)]
Insights
Dobutamine effectively improved cardiac function in patients with severe heart failure, enhancing cardiac output and left ventricular performance without significant arrhythmias. This positive inotropic agent shows promise for treating low-output syndrome.
Area of Science:
- Pharmacology
- Cardiology
- Physiology
Context:
- Severe cardiac failure presents significant challenges in management.
- The low-output syndrome is a critical manifestation of cardiac decompensation.
- Positive inotropic agents are essential for improving myocardial contractility.
Purpose:
- To evaluate the efficacy and safety of dobutamine in patients with cardiac failure.
- To assess the hemodynamic effects of dobutamine infusion.
- To determine the optimal dosage for therapeutic benefit.
Summary:
- Dobutamine infusion (5 and 7.5 mug/kg-min) improved cardiac output by 33% and left ventricular ejection fraction from 29% to 39% in 9 patients.
- End-diastolic pressure decreased, and mean circumferential fiber contraction velocity doubled, indicating enhanced ventricular function.
- Systolic aortic pressure increased, while systemic circulation resistance decreased, with minimal changes in heart rate and no increased arrhythmia tendency.
Impact:
- Dobutamine demonstrates selective myocardial beta-1 receptor activity.
- Results suggest dobutamine is a successful therapeutic option for severe cardiac failure, especially in low-output syndrome.
- This study supports the use of dobutamine for acute hemodynamic support in critically ill cardiac patients.
Abstract:
Dobutamine, a new catecholamine with a positive inotropic action, was given by infusion to 9 patients with cardiac failure in a dosage of 5 and 7.5 mug/kg-min over a period of 15 minutes. An improvement of left ventricular function was proven by an increase of cardiac output by 33%, a reduction of end-diastolic pressure from 21 to 14 mm Hg, an improvement of left ventricular ejection fraction from 29 to 39% and of the mean circumferential fibre contraction velocity from 0.4 to 0.8 circ/s. The systolic aortic pressure increased by a mean of 14% (5 mug/kg-min) and 23% (7.5 mug/kg-min). However, the resistance of the systemic circulation decreased from 1858 to 1439 and 1444 dyn-s-cm-5. Cardiac frequency remained unchanged with a dosage of 5 mug/kg-min and increased by a mere 7 beats/min with a dosage of 7.5 mug/kg-min. There was no increased tendency for arrhythmia. Dobutamine thus appears to act relatively selectively on myocardial beta-1 receptors. Results so far indicate therapeutic success in patients with severe cardiac failure, particularly in the low-output syndrome.